Ireland
--:--IST
Recruiting Observational

Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions

NCT03667196 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2018-01-11
Last updated
2026-06-25

Condition(s) studied

Chronic Total Occlusion of Coronary Artery

Investigational drug(s) / intervention(s)

antegrade and retrograde approach

antegrade and retrograde approach: This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO

Study summary

Objective of this study is to 1) analyze the clinical, anatomical and periprocedural differences of patients who underwent a procedure related to coronary CTO through the antergrade approach and retrograde approach; 2) analyze the success rate of the procedures and the incidence and patterns of complications; 3) compare and analyze long-term performances after the successful procedure; and 4) identify the independent factors that require a retrograde approach and the prognostic factor regarding long-term performances after use of each approach.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged\>=19 * Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5 mm in blood vessel diameter * Patients who have symptoms of angina or objectively proven myocardial ischemia (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment elevation myocardial infarction) * Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or let their representative do this), and signed the informed consent form approved by the IRB of each study institute Exclusion Criteria: * Patients who are pregnant or lactating or have childbearing potential Patients in whom contrast medium and heparin are contraindicated or who are hypersensitive to them * Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are contraindicated * Patients scheduled to undergo a surgery, etc. that requires discontinuance of an antiplatelet drug within 12 months after participation in the study * Acute ST elevation myocardial infarction at the time of hospitalization * Terminally ill patients with their life expectancy \< one year * Patients who have serious diseases other than cardiac diseases that may affect limitation of residual life time or observation of the protocol (e.g. oxygen-independent chronic obstructive pulmonary disease, persisting hepatitis or serious hepatic insufficiency, severe renal disease, etc. Be left up to the discretion of the investigator.)

Primary outcome measure(s)

  • Death — 12-month after PCI
    Death
  • myocardial infarction — 12-month after PCI
    the periprocedural myocardial infarction under the SCAI definition or the non-lethal myocardial infarction during the follow-up observations
  • the complex endpoints of target vessel revascularization/reocclusion occurrence — 12-month after PCI
    including chronic total occlusion and angiostenosis

Trial sites (32)

FacilityCityRegionStatus
Hallym University Sacred Heart Hospital Anyang South Korea Recruiting
SoonChunHyang University Hospital Bucheon Bucheon-si South Korea Recruiting
Gyeongsang National University Changwon Hospital Changwon South Korea Recruiting
Chungbuk National University Hospital Cheongju-si South Korea Recruiting
Gangwon National University Hospital Chuncheon South Korea Recruiting
Keimyung University Dongsan Medical Center Daegu South Korea Recruiting
Yeungnam University Medical Center Daegu South Korea Recruiting
Chungnam National University Hospital Daejeon South Korea Recruiting
the Catholic University of Korea, Daejeon St. Mary'S Hospital Daejeon South Korea Recruiting
The Catholic University of Korea, ST. Vincent's Hospital Daejeon South Korea Recruiting
Gangneung Asan Hospital Gangneung South Korea Recruiting
Myongji Hospital Goyang-si South Korea Recruiting
Hanyang University Medical Center Guri-si South Korea Recruiting
Gwangju Veterans Hospital, Korea Veterans Health Service Gwangju South Korea Recruiting
Chung-Ang University Gwangmyeong Hospital Gwangmyeong South Korea Recruiting
Seoul national university Bundang hospital Gyeonggi-do South Korea Recruiting
Inha University Hospital Incheon South Korea Terminated
The Catholic University of Korea, Incheon ST. MARY'S Hospital Incheon South Korea Recruiting
Busan Veterans Hospital, Korea Veterans Health Service Pusan South Korea Recruiting
Dong-A University Hospital Pusan South Korea Recruiting
Gosin University Gospel Hospital Pusan South Korea Recruiting
Inje University Haeundae Paik Hospital Pusan South Korea Recruiting
Inje University Pusan Paik Hospital Pusan South Korea Recruiting
Chungnam National University Sejong Hospital Sejong South Korea Recruiting
Asan Medical Center Seoul South Korea Recruiting
Kangbuk Samsung Hospital Seoul South Korea Terminated
Samsung Medical Center Seoul South Korea Recruiting
The Catholic University of Korea, Eunpyeong Seoul South Korea Recruiting
The Catholic University of Seoul St. Mary's Hospital Seoul South Korea Recruiting
Veterans Hospital Service Medical Center Seoul South Korea Recruiting
Ulsan University Hospital Ulsan South Korea Recruiting
Pusan National University Yangsan Hospital Yangsan South Korea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03667196 on ClinicalTrials.gov ↗ ← All trials in South Korea